HomeCompareVAPO vs ARCC

VAPO vs ARCC: Dividend Comparison 2026

VAPO yields 92.17% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VAPO wins by $2.79M in total portfolio value
10 years
VAPO
VAPO
● Live price
92.17%
Share price
$2.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.81M
Annual income
$897,478.47
Full VAPO calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — VAPO vs ARCC

📍 VAPO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVAPOARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VAPO + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VAPO pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VAPO
Annual income on $10K today (after 15% tax)
$7,834.10/yr
After 10yr DRIP, annual income (after tax)
$762,856.70/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, VAPO beats the other by $762,855.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VAPO + ARCC for your $10,000?

VAPO: 50%ARCC: 50%
100% ARCC50/50100% VAPO
Portfolio after 10yr
$1.42M
Annual income
$448,739.81/yr
Blended yield
31.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

VAPO
Analyst Ratings
2
Buy
3
Hold
1
Sell
Consensus: Hold
Price Target
$1.60
-26.3% upside vs current
Range: $1.60 — $1.60
Altman Z
-14.2
Piotroski
4/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VAPO buys
0
ARCC buys
0
No recent congressional trades found for VAPO or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVAPOARCC
Forward yield92.17%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$2.81M$24.5K
Annual income after 10y$897,478.47$1.16
Total dividends collected$2.49M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy
Analyst price target$1.60$21.88

Year-by-year: VAPO vs ARCC ($10,000, DRIP)

YearVAPO PortfolioVAPO Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$19,917$9,216.59$11,381$541.15+$8.5KVAPO
2$38,466$17,155.42$12,621$284.08+$25.8KVAPO
3$72,125$30,965.76$13,827$145.31+$58.3KVAPO
4$131,436$54,262.79$15,062$73.43+$116.4KVAPO
5$233,053$92,416.55$16,364$36.89+$216.7KVAPO
6$402,513$153,146.25$17,757$18.49+$384.8KVAPO
7$677,889$247,199.53$19,258$9.25+$658.6KVAPO
8$1,114,424$389,082.88$20,880$4.63+$1.09MVAPO
9$1,790,226$597,792.36$22,636$2.32+$1.77MVAPO
10$2,813,020$897,478.47$24,539$1.16+$2.79MVAPO

VAPO vs ARCC: Complete Analysis 2026

VAPOStock

Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.

Full VAPO Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this VAPO vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VAPO vs SCHDVAPO vs JEPIVAPO vs OVAPO vs KOVAPO vs MAINVAPO vs HTGCVAPO vs GBDCVAPO vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.